Blog

Explore phage display technology for antibody discovery, drug development, and vaccine research, and its role in engineering high-affinity monoclonal antibodies and peptide drugs.

Biointron’s ISO 9001:2015-certified manufacturing standards ensure reliable, high-quality antibody production with rigorous QC processes and global CRO expertise.

Learn about VHH antibodies, their history, diagnostic and therapeutic applications, and their role in advanced platforms like ELISA, biosensors, and targeted medicine.

Biointron delivers advanced bispecific antibody production with over 260 proven formats, offering rapid expression, scalable solutions, and trusted CRO expertise for therapeutic development.

Automation transforms antibody workflows. Discover robotic systems and integrated platforms that raise throughput, consistency, and data confidence.

Understand affinity maturation from natural immune processes to Biointron’s FCMES-AM™ platform, enhancing antibody affinity, specificity, and therapeutic performance.

Learn how antibody humanization reduces immunogenicity in therapies. Explore CDR grafting, phage display, and Biointron’s rapid humanization services.

Discover how hybridoma sequencing prevents cell line loss, ensures accurate antibody sequences, and enables recombinant expression for consistent, scalable antibody production.

High-throughput antibody production changes the pace of biotech. Learn how automation and  Single B Cell Screening deliver thousands of antibodies with speed and quality.

The alpaca advantage: VHH discovery powered by unique immune repertoires. See how Biointron leverages alpaca libraries for robust nanobody identification.

Explore the dual roles of autoantibodies in health and autoimmune diseases, acting as immune defenders and disruptors in lupus, COVID-19, and chronic inflammation.

Combination antibody therapies enhance efficacy by targeting multiple pathways. Biointron showcases synergistic strategies that improve outcomes in cancer and infectious diseases.